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DiarrheaAn infant developed a severe condition of recurrent and persistent watery diarrhea at 40 days of age. The child
had been partially breast-fed, and the mother used topiramate for epilepsy. Hospital examination excluded a
viral or bacterial infection and failed to identify any other potential cause. After twoweeks, topiramate exposure
was suspected to be the cause, and breast-feedingwas suspended. The diarrhea ceasedwithin 2 days. Analysis of
the breast milk showed a topiramate concentration of 15.7 μmol/L (5.3 μg/mL). There is little information on the
use of topiramate in breast-feeding women. The potential effects on the children are not known. Topiramate
passes into breast milk, and the concentration may equal the therapeutic plasma concentration. In this case,
the infant may have ingested up to 40% of the mother's weight-adjusted dose. Diarrhea is a well-known adverse
reaction to topiramate and has the potential to cause serious electrolyte disturbances inneonates and infants. The
condition improved rapidly after suspension of breast-feeding. Topiramate in breast milk may reach levels that
cause adverse effects in infants. Based on the adverse reaction proﬁle of topiramate and the milk concentration,
the diarrhea was assessed as a probable adverse drug reaction in the infant.
© 2013 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Topiramate is one of the newer antiepileptic drugs and is also ap-
proved for migraine prophylaxis [1]. There is little information
concerning topiramate use in breast-feeding women, but case reports
indicate that it is transferred into human milk and that milk concentra-
tions may equal those in maternal plasma [2–5]. We report a case of
long-lasting diarrhea in a breast-fed infant exposed to topiramate.
2. Case report
A patient with epilepsy, aged 31, had been treated with topiramate
100 mg/day for several years. The treatment was continued unchangederms of the Creative Commons
rmits non-commercial use, dis-
original author and source are
yHospital, Ulleval, PO Box 4956
rgren).
rug Abuse Research, Norwegian
ed by Elsevier Inc. This is an open accethroughout her pregnancy with good therapeutic effect. A healthy girl
with a birth weight of 2735 g was born after an induced birth 2 days
after term. The topiramate treatment was continued while breast-
feeding. In order to reduce infant exposure to topiramate, two daily
breast milk meals were replaced with formula meals a week after
birth. The baby initially thrived and had a normal development. At
40 days of age and body weight of 4735 g, she became ill, with 8–10
watery, foamy stools a day. No other family member had diarrhea or
gastrointestinal upset. Her weight gain rate eventually declined, and
she was referred to the hospital outpatient clinic. Relevant differential
diagnoses such as infection or somatic cause of the diarrhea were ex-
cluded, but she still suffered from diarrhea. After 18 days of frequent,
watery stools, the general practitioner suspected a causal relationship
with topiramate, and breast-feeding was suspended. Within 2 days,
the frequencywas reduced to 2–3 stools a day, and themother observed
more solid feces, with smell and color returning to normal.
While breast-feeding was suspended, the mother used a breast
pump and stored the milk in a freezer (−20 °C). She gave her consent
to have the milk analyzed for topiramate, and the milk was sent for
analysis after a storage time of 4.5 months. A sample was analyzed for
topiramate by ﬂuorescence polarization immunoassay based on the
competitive binding principle (Innoﬂuor Topiramate Assay System,
Seradyn, Indianapolis, IN, U.S.A.). The assay system was used on a TDxss article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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was 0.3 μg/mL (0.89 μmol/L). Precision studies have shown a coefﬁcient
of variation (CV) of b5%. The analysis showed a topiramate concentra-
tion of 15.7 μmol/L in the mother's milk, corresponding to 5.3 μg/mL.
The plasma concentration in the child was not measured.3. Discussion
Breast-feeding is generally recommended, even if the mother is
using antiepileptic drugs, but adverse effects in the child may necessi-
tate reduction or withdrawal of breast-feeding. Little is known regard-
ing the use of topiramate in breast-feeding women and the risk of
adverse effects in their children. Animal studies have demonstrated
the excretion of topiramate in milk [6]. While there are no systematic
studies of topiramate excretion in humanmilk, some study results indi-
cate a considerable transfer. The product information does not state ex-
plicitly that topiramate is contraindicated during breast-feeding but
advises that a risk/beneﬁt assessment should be made before deciding
whether to stop breast-feeding or to withdraw topiramate [6].
A literature search in Medline Ovid, EMBASE, handbooks, and data-
bases on drugs and lactation provided little additional information. Pub-
lished case reports of topiramate use while breast-feeding [2–5] include
a total of only eight patients. A general ﬁnding is transfer into breast
milk and milk/plasma ratios of 0.6–1.1. Concentrations of topiramate
in the breast milk of three patients were 1.6–3.6, 6.9, and 13.7 μmol/L
(0.5, 2.3, and 4.7 μg/mL), respectively, after daily doses of 150 or
200 mg, measured 14–97 days after delivery. Theweight-adjusted rela-
tive dose to the infantwas estimated at 3–23%of thematernal dose. Two
of themotherswere using carbamazepine, a substance known to induce
the metabolism of topiramate [3]. Another case report found a
topiramate concentration of 3.1 μg/mL (9.1 μmol/L) after a daily dose
of 150 mg in one patient 12 days after delivery [5]. We have not found
any studies investigating stability of topiramate in breast milk, but
topiramate in human plasma stored for a period of 1 month at−80 °C
has shown that the drug is stable [7]. Topiramate is not metabolized to
any great extent unless the patient is using concomitant CYP enzyme in-
ducers [6].
The child's plasma concentration will depend on the amount of
drug in the milk, the amount absorbed from the intestine of the
child, and the child's ability to eliminate the compound. In ﬁve of
six mother/infant pairs, plasma levels of topiramate in the infants
were 10–20% of the maternal plasma levels and in one case couldnot be detected [2,3]. In the case reported here, a milk concentration
of 5.3 μg/mL (15.7 μmol/L) and an estimated daily intake of 450 mL
of mother's milk in an infant weighing 4735 g would result in a
daily dose of 0.5-mg/kg topiramate. Other case reports have de-
scribed theoretical infant dosages of 0.1–0.7 mg/kg/day [3] and
0.6 mg/kg/day [5]. The mother's body weight was 70 kg, and the rel-
ative infant dose was estimated at 0.35. The infant described here
may have ingested a topiramate dose of 35% of the mother's
weight-adjusted dose.
Withdrawal of breast milk was associated with rapid clinical im-
provement of the child's condition, supporting the theory of an adverse
drug reaction. Diarrhea is a well-known and very common adverse re-
action to topiramate [6], and the infant's condition improved upon
withdrawal of topiramate. The diarrhea was assessed as a probable ad-
verse reaction to topiramate in the breast milk. Other case reports de-
scribing topiramate use in breast-feeding women do not describe side
effects in the children. To our knowledge, this is the ﬁrst report of prob-
able topiramate-induced diarrhea in a breast-fed infant. Infant diarrhea
increases the risk of electrolyte disturbances, and topiramate in the
breast milk may be a hitherto unknown risk factor.
The case has been reported to the National Health Authorities in
Norway, registered as number NO-NOMAADVRE-RELISS-2008-5232.
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